Related Experiment Video
Updated: Aug 4, 2026
11:01
Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
Published on: August 30, 2011
P300 and Alzheimer's disease
1Department of Neuropharmacology, Research Institute of Scripps Clinic, La Jolla, CA 92037.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|January 1, 1989
Summary
The P3 event-related potential (ERP) can help diagnose dementia. This brainwave measure shows promise for assessing early Alzheimer's disease, aiding clinicians in diagnosis.
Area of Science:
- Neuroscience
- Cognitive Science
- Medical Diagnostics
Background:
- Dementing illnesses, including Alzheimer's disease, pose significant diagnostic challenges.
- Event-related potentials (ERPs), specifically the P300 or P3 component, have been explored as potential biomarkers.
- Early and accurate diagnosis is crucial for effective management and treatment of dementia.
Purpose of the Study:
- To review previous research on P3 ERPs in dementing illnesses.
- To present recent findings on using P3 techniques for early Alzheimer's disease diagnosis.
- To evaluate the utility of P3 ERPs in diagnosing dementia and assessing early-stage Alzheimer's disease.
Main Methods:
- Review of existing literature on P3 ERP studies in dementia.
- Presentation and analysis of recent experimental results applying P3 techniques.
- Focus on the diagnostic and assessment capabilities of P3 ERPs.
Main Results:
- Data suggest P3 ERPs are sensitive to cognitive changes associated with dementia.
- Recent findings indicate P3 techniques can be applied to diagnose early Alzheimer's disease.
- The P3 component shows potential as a reliable diagnostic aid.
Conclusions:
- The P3 event-related potential (ERP) is a valuable tool for dementia diagnosis.
- P3 ERP assessment can aid in the early identification and evaluation of Alzheimer's disease.
- Further research and clinical application of P3 ERPs are warranted for dementia assessment.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...